Mature in Biological Technology

MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan

... "Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific ... is entitled: "Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific ... DC, followed by maturation. Direct loading of mature DC also saves significant processing time. Using ...

Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community

... medicines, cardiovascular and metabolic drugs, mature pharmaceutical brands and the Health Care Group, ... back assets in its profitable, though declining, mature brands. The company is seeking opportunities to ... -- reducing the number of brands in the company's mature products portfolio by 60 percent between ...

Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies

... cells in vivo (in the body) and by reprogramming mature adult cells into stem cells. "Fate's approach ... platform involves developing drugs to reprogram mature adult cells into stem cells which when ... Vice President Tom St. John. "The science is now mature enough. Clear therapeutic modalities have ...

Beckman Coulter Prices $500 Million Senior Notes Offering

... notes offering of: $250 million of Senior Notes that mature in 2015 and bear interest at a rate of 6%, and $250 million of Senior Notes that mature in 2019 and bear interest at a rate of 7%. (Logo: ...

Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million

... fell back to a more normal level in 2008 as our brands reached a more mature position and extra promotions were not as necessary. Research ... toward future revenues, Mr. Xueyun Cui Stated, ''The TP-5 market is mature and is highly competitive while the markets for Somatostatin, DDAVP and ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... the control arm. Additional survival updates are needed before a mature median survival for the OGX-011 arm can be reported; however, ... chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of ....

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... 30 months for both arms. Additional survival updates are needed before a mature median survival for the OGX-011 arm can be reported. Based on the current ... arm can not be lower than 22.7 months. An abstract presenting the mature results is planned to be submitted to the American Society of Clinical ...

Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants

... (GVHD). GVHD is a potentially fatal complication that can occur when mature donor T cells that are transferred along with stem cells from donated ... like leukemia. "Following allogeneic blood and marrow transplantation, mature donor T cells can enhance the engraftment process to grow new stem cells, ...

Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.

... used in the fields of nephrology and endocrinology. Fontus focuses on mature products with widely accepted clinical value and brand loyalty. Fontus ... equity fund that founds and invests in portfolio companies that acquire mature prescription drug brands that offer important therapeutic benefits. For ...

Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011

... treatment market grew nearly 70% between 2001 and 2006 with conventional, mature products generating the majority of sales. Although the market has ... Anne Crandall, the report's author. "Competitors that offer traditional mature products must look for ways to incorporate advanced wound care products ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... 21% and 3%, respectively. Base Medical Products. Certain of our product lines, which we refer to as our Base Medical Products, represent more mature finished goods product lines in the ophthalmology, biopsy and general surgery areas, or medical device components manufactured by us and sold to ...

Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development

... chemicals. His capabilities include strong leadership, and strategic and organizational skills that have produced positive results in early stage and mature businesses." Most recently Dan served as Executive Director of Contract Manufacturing at Ben Venue Laboratories where he was responsible for ...

Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts

... from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the ...

Stem cells' 'suspended' state preserved by key step, scientists report

... the finding may lead to a greater understanding of how cells acquire their specialized states and provide a strategy to efficiently reprogram mature cells back into the pluripotent state, an elusive step in stem cell research but one crucial to a range of potential clinical treatments. The ...

Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders

... are 6,826,500 shares of Series A Preferred Stock outstanding, which are convertible into shares of Tianyin's common stock at $1.60 per share and mature in January 2011. Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "We appreciate the continued support of both ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... understand how islets of Langerhans, the endocrine component of the pancreas, are formed during organogenesis, how their function is regulated in the mature organism, and how changes in gene expression might allow islet regeneration. Dr. Amy Wagers, assistant professor in the Section on ...

Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

... as in most other industries. As such, sales of pharmaceuticals are expected to slowdown in 2009 and 2010, with declines or flat growth expected in mature markets such as the US, Japan, and Western Europe. The effects of the global economic downturn are expected to vary in different markets owing to the ...

Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion

... associated with the bankruptcy proceeding. The DIP Facility will accrue interest at the rate of 10% per annum (with a default rate of 18%) and will mature on the date a plan of reorganization is approved by the Bankruptcy Court, subject to acceleration upon certain event of defaults set forth in the DIP ...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

... stimulator, or BLyS(R). BLyS is a naturally occurring protein discovered by HGS that is required for the development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body's first line of defense against infection. In lupus and certain other autoimmune ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... Increase in Progression Free Survival 4.7 months vs. 2.6 months; p=0.007 Positive trend in Overall Survival even though data not fully mature with median 8.1 month vs. 6.9 month; p=0.544 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the ...

Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings

... notes will bear interest at a rate of 2.50% per year, payable on May 1 and November 1 of each year, commencing on November 1, 2009. The notes will mature on May 1, 2014. Holders may require the Company to repurchase all or a portion of their notes upon a fundamental change (as defined in the ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... are scheduled to be held as shown below at the ASCO Annual Meeting in Orlando, Florida. Presentation Information Title: mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in ...

OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting

... will also include new data that has been updated since abstracts were submitted to ASCO. Abstract Presentation Information Title: mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in ...

Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University

... (OTD) is to promote commercialization of technologies arising from Boston University faculty research. Whether it begins with novel concepts, mature academic technologies or emerging companies, OTD's suite of support services and expertise provides the opportunity to achieve success at every stage ...

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

... been 35% and 10% respectively. Base Medical Products. Certain of our product lines, which constitute our Base Medical Products, represent more mature finished goods product lines in the general surgery and ophthalmology areas or medical device components manufactured by us and sold to other third ...

Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

... has a track record of introducing more than 15 pharmaceutical products to market. Pharmalink currently has three clinical phase development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... of treatment with either the anti-HSV or the anti-HIV L.E.A.P.S. vaccine, human blood cell monocytes purified from several different donors became mature dendritic cells. The transition was indicated by the expression of cell surface proteins, cell appearance and production of IL-12. Unlike monocytes ...

Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology

... into the discovery and development of safer and more effective therapeutics." iPS cells are made by "reprogramming" fully differentiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos. Because iPS ...

Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development

... has a track record of introducing more than 15 pharmaceutical products to market. Pharmalink currently has three clinical phase development projects mature for out-licensing: Nefecon(R), an effective treatment of IgA nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio ...

Immunotherapy-Based Provisional Patents Mark Significant Discovery

... immunogen (a cancer target against which the immune system is directed) found in many tumor cell lines or fetal tissue, but not found in normal mature tissue. This makes it a unique target for personalized anti-cancer therapy for multiple cancers. The company is currently conducting clinical trials ...

Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products

... kits has the potential to have a significant impact. Recent studies with Pfizer scientists have demonstrated that the AdipoDesign Kits produce mature adipocytes that exhibit physiologically relevant responses in a variety of predictive assays. The results from these studies were presented at ...

New Brain Fitness Survey Reinforces Importance of Brain Awareness Week

... problems in more depth (including research, health culture, lack of assessment, other), and suggest actions to solve them and help the field mature in a more rational and structured manner. Everyone: Have a great Brain Awareness Week! About SharpBrains: SharpBrains is the leading ...

New organic material may speed Internet access

... Silicon, on the other hand, is structurally suited to the dense integration of components on photonic circuit devices. And silicon technology is mature and precise. It enables the creation of waveguides whose nanoscale flatness facilitates the control of light propagation. "With pure silicon," ...

Index Ventures Closes Euro 350 Million Early Stage Fund

... side, Index is focused on finding the best companies with the strongest pipelines. We are equally interested in very early stage ventures and more mature companies with established proof-of-concept. In terms of therapeutic areas, our priorities are oncology, CNS, immunology and inflammation. We ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... debt or facilities maturing in the next three years and substantially all of Shire's debt relates to its $1.1 billion 2.75% convertible bonds which mature in 2014, although these include a put option which could require repayment in 2012. In addition, Shire has a committed facility until 2012 of $1.2 ...

SenesTech, Inc. Appoints Susan Airhart to Board of Directors

... launching successful business plans, lab management for a bi-coastal national lab, generation of year over year revenue growth in both emerging and mature markets, out- and in-licensing technologies to build revenue and product development management. She is currently Senior Director of Strategic ...

ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference

... will comment on the future of pharma. Bernard will focus on understanding the implications and applications of U.S. Pharma's transition to a mature industry for managed markets marketing. Douglas Jordan, senior vice president and managed markets practice leader, Euro RSCG Life, will be ...

Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug

... and Chief Executive Officer of Isis. "We have 19 drugs in our pipeline and with the efficiency of our antisense technology, we expect to continue to mature and expand our portfolio as drugs advance in clinical development and are added to the pipeline." About SGLT2 and ISIS-SGLT2Rx SGLT2 is ...

Stem Cell Innovations' PluriCells(TM) to Form the Basis of a Liver Assist Device to Support Patients Waiting for Transplant.

... using our PluriCell(TM) system to understand the requirements of the liver stem cell and our ACTIVTox system to understand the requirements of the mature cell." Liver disease is a serious problem in the United States and worldwide. There are about 6,500 liver transplantations performed each year ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%. For comparison, published studies using a platinum-based regimen plus ...